Niagen Bioscience (NAGE) director receives 31,746 stock options at $3.45 strike

Rhea-AI Filing Summary

Niagen Bioscience director Yu Wing Tak Wendy received a grant of stock options covering 31,746 shares of Common Stock. The options have an exercise price of $3.45 per share, vest 100% on June 24, 2027, and expire on June 23, 2036. Following this compensation grant, she holds 31,746 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider YU Wing Tak Wendy

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	31,746	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 31,746 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 31,746 options Exercise price: $3.45 per share Total options after grant: 31,746 options +3 more

6 metrics

Stock options granted 31,746 options Grant to director on June 24, 2026

Exercise price $3.45 per share Stock option exercise price

Total options after grant 31,746 options Total derivative holdings following transaction

Vesting date June 24, 2027 Options vest 100% on this date

Expiration date June 23, 2036 Option expiration

Transaction price per option $0.00 Grant/award acquisition price

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, Common Stock, director

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

director financial

"is_director: 1 for reporting person"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 06:03 PM Accepted by SEC EDGAR 06/26/2026 - 06:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YU Wing Tak Wendy

(Last) (First) (Middle)

10900 WILSHIRE BLVD. SUITE 600

(Street)

LOS ANGELES CALIFORNIA 90024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.45	06/24/2026		A		31,746		06/24/2027(1)	06/23/2036	Common Stock	31,746	$0	31,746	D

Explanation of Responses:

1. Option vests 100% on June 24, 2027.

Remarks:

	/s/ Jeong James Lee, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Niagen Bioscience (NAGE) disclose in this Form 4?

Niagen Bioscience reported a stock option grant to director Yu Wing Tak Wendy. She received options over 31,746 Common Stock shares as part of compensation, with specific vesting and expiration terms outlined in the filing.

How many stock options were granted to the Niagen Bioscience director?

The director received stock options for 31,746 shares of Common Stock. These options represent the entire derivative holding reported in this filing and are held directly by Yu Wing Tak Wendy after the grant.

What is the exercise price of the Niagen Bioscience (NAGE) stock options?

The exercise price of the granted stock options is $3.45 per share. This is the price at which the director can buy Niagen Bioscience Common Stock once the options vest, according to the Form 4 disclosure.

When do the director’s Niagen Bioscience stock options vest and expire?

The options vest 100% on June 24, 2027, according to the footnote. They expire on June 23, 2036, giving the director several years after vesting to exercise the options if she chooses.

Is this Niagen Bioscience Form 4 an open-market buy or a compensation grant?

This Form 4 reflects a compensation grant, not an open-market purchase. The transaction code is A, described as a grant, award, or other acquisition, with the transaction price reported as $0.00 per option.

How many Niagen Bioscience stock options does the director hold after this grant?

After the reported transaction, the director holds 31,746 stock options. The total shares following the transaction equal the number of options granted, indicating this is her reported derivative position in this filing.